ConductScience.org, home

Trial · NCT00838630

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

NCT00838630, Phase 1, Completed, Teva Pharmaceuticals USA; results first posted 2009-07-21

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Cilostazol 100 mg Tablet Formulations Under Fasting Conditions. Trials, record NCT00838630. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00838630

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Cilostazol 100 mg Tablet Formulations Under Fasting Conditions
NCT number
NCT00838630
Status
Completed
Phases
Phase 1
Enrollment
36 participants, actual
Lead sponsor
Teva Pharmaceuticals USA
Conditions
Healthy
Interventions
Cilostazol 100 mg tablets, Pletal® 100 mg tablets
First posted
2009-02-06
Last updated
2024-08-19
Results first posted
2009-07-21

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryCmax - Maximum Observed ConcentrationBlood samples collected over 96 hour periodBioequivalence based on Cmax
PrimaryAUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)Blood samples collected over 96 hour periodBioequivalence based on AUC0-inf
PrimaryAUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero ConcentrationBlood samples collected over 96 hour periodBioequivalence based on AUC0-t

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYCmax - Maximum Observed ConcentrationBlood samples collected over 96 hour periodData from subjects who completed the study were included in the statistical analysis.ng/mLMEAN
PRIMARYAUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)Blood samples collected over 96 hour periodData from subjects who completed the study were included in the statistical analysis.ng*h/mLMEAN
PRIMARYAUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero ConcentrationBlood samples collected over 96 hour periodData from subjects who completed the study were included in the statistical analysis.ng*h/mLMEAN

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Cmax - Maximum Observed ConcentrationCilostazol536Standard Deviation 147ng/mL
Cmax - Maximum Observed ConcentrationPletal®543Standard Deviation 145ng/mL
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)Cilostazol8670Standard Deviation 3626ng*h/mL
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)Pletal®8974Standard Deviation 3147ng*h/mL
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero ConcentrationCilostazol8430Standard Deviation 3507ng*h/mL
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero ConcentrationPletal®8634Standard Deviation 3104ng*h/mL

Participant flow18

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
First InterventionSTARTEDCilostazol (Test) First18
First InterventionSTARTEDPletal® (Reference) First18
First InterventionCOMPLETEDCilostazol (Test) First17
First InterventionCOMPLETEDPletal® (Reference) First18
First InterventionNOT COMPLETEDCilostazol (Test) First1
First InterventionNOT COMPLETEDPletal® (Reference) First0
Washout: 7 DaysSTARTEDCilostazol (Test) First17
Washout: 7 DaysSTARTEDPletal® (Reference) First18
Washout: 7 DaysCOMPLETEDCilostazol (Test) First16
Washout: 7 DaysCOMPLETEDPletal® (Reference) First18

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00838630

GET https://conductscience.org/api/trials/v1/NCT00838630/registered